Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda's $13.6 Bil. Nycomed Buy Meets Multiple Strategic, Financial Imperatives

Executive Summary

Takeda Pharmaceuticals Co. Ltd.'s €9.6 billion ($13.6 billion) purchase of privately held Nycomed AS, confirmed May 19 after a week of speculation, satisfies a number of strategic and financial imperatives for Japan's largest drug maker, as it faces generic competition to best-selling diabetes drug Actos (pioglitazone) from 2012 and seeks to expand its footprint beyond Japan and the U.S.

You may also be interested in...



Deal Watch: Valeant’s Financial/Commercial Strength Offers A New Chance For Provenge

AstraZeneca buys out respiratory franchise from Actavis, which it had gained a year prior with its purchase of Forest. Mylan announced two deals Feb. 2, collaborating in COPD with Theravance and buying women’s health products from India’s Famy Care.

Deals Of The Week: Big Pharmas Hoard Cash, But Aren’t Buying Yet In 2013

DOTW digs into a Moody’s report detailing which companies’ balance sheets have the most cash, even if the pharmas that made the cut haven’t been putting their purchasing power to work. In addition, details on Valeant’s latest dermatology acquisition, Merck’s deal with Cerecor for a portfolio of COMT assets, Janssen’s European cancer research tie-up, and an NPS/Takeda deal for orphan drugs.

NPS Moves Toward Status As Global Orphan Drug Firm With Takeda Agreement

In a deal that moves a $50 million equity stake to Takeda, NPS reacquires ex-U.S. rights to teduglutide and PTH 1-84, enabling the New Jersey firm to position itself as a worldwide orphan drug specialist. Takeda also can earn a $30 million one-time, sales-dependent milestone under the deal.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS053429

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel